INCB 053914

Drug Profile

INCB 053914

Alternative Names: INCB 53914

Latest Information Update: 30 Oct 2015

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class
  • Mechanism of Action PIM3 protein inhibitors; Proto oncogene proteins c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Preclinical Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 01 Oct 2015 Phase-I/II clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02587598)
  • 29 May 2015 Pharmacodynamics data from preclinical studies in Multiple myeloma and Acute myeloid leukaemia released by Incytes (3125310 & 3125312)
  • 01 Jan 2015 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top